Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

What's the purpose of this trial?

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Following diagnoses are eligible for inclusion in the study:
    • Multiple Myeloma with ASCT used as consolidation after first line induction therapy or at first relapse.
    • Relapsed Hodgkin's disease C) Non-Hodgkin's Lymphomas as follows
      • Relapsed Diffuse large B cell lymphoma
      • Relapsed indolent or relapsed transformed indolent B cell lymphomas as consolidation after second line therapy
      • Mantle Cell lymphoma as consolidation after first-line therapy
      • Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse
  • Patients undergoing first ASCT will be eligible for the study.
  • Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed.
  • Age ≥18 years
  • Life expectancy of greater than 6 months.

Exclusion Criteria:

  • Previously exposure to a CD38 antibody during the last 12 months.
  • Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks.
  • History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and Lactating women
  • HIV-positive status due to increased risk of infection when treated with immunosuppressive therapy

Additional Trial Information

Phase 2

Enrollment: 39 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

New York, NY

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message